Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • ATS-9R: Targeted Gene Silencing in White Adipose Tissue

    2026-02-05

    ATS-9R: Targeted Gene Silencing in White Adipose Tissue

    Introduction: Revolutionizing Gene Delivery to Adipocytes

    Obesity and its complications—insulin resistance, type 2 diabetes, and gestational diabetes mellitus (GDM)—are driven in part by dysfunctional white adipose tissue (WAT). Research in these areas demands tools capable of delivering gene-modifying agents with precision and safety. ATS-9R (Adipocyte-targeting sequence-9-arginine), a non-viral gene delivery fusion oligopeptide supplied by APExBIO, offers an innovative solution for scientists aiming to silence genes specifically in adipocytes. By leveraging Prohibitin-mediated endocytosis and a potent nona-arginine (9R) motif, ATS-9R enables targeted delivery of shRNA, sgRNA/Cas9 complexes, and other nucleic acids directly into white adipose tissue, minimizing off-target effects and cytotoxicity.

    Principle and Setup: How ATS-9R Enables Precision Targeting

    ATS-9R is engineered as a fusion oligopeptide with the sequence Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Cys. Its design incorporates two key features:

    • Adipocyte specificity via a Prohibitin-binding motif, ensuring selective uptake by mature white adipocytes and visceral adipose tissue macrophages (ATMs).
    • Nona-arginine domain (9R) that condenses nucleic acids into nanoparticles (150–354 nm; zeta potential 7–20 mV) and enhances cell penetration.

    Upon binding to Prohibitin—abundantly expressed on adipocyte surfaces—ATS-9R/nucleic acid complexes are internalized by endocytosis, releasing their genetic cargo efficiently. This enables robust gene silencing with minimal distribution to non-target tissues and rapid hepatic clearance (within 12–24 hours).

    Step-by-Step Workflow: Optimized Protocol for ATS-9R-Mediated Delivery

    1. Complex Preparation

    • Dilute ATS-9R in DMSO and nucleic acids (shRNA, sgRNA/Cas9, etc.) in nuclease-free water. Prepare fresh for each experiment and keep on ice.
    • Mix at a weight ratio of 3:1 or 6:1 (ATS-9R:nucleic acid). For instance, combine 18 μg peptide with 6 μg nucleic acid or 36 μg with 6 μg. Incubate at room temperature for 20–30 minutes to allow nanoparticle formation.
    • Confirm condensation via agarose gel retardation assay—complexes should not migrate, indicating complete condensation.

    2. Cell Culture/In Vitro Transfection

    • Seed mature 3T3-L1 adipocytes or primary adipocyte cultures in serum-free medium.
    • Add complexes to a final peptide concentration of 10–25 μg/ml and nucleic acid 5 μM–2 μg per well (based on plate format).
    • Incubate for 4–6 hours, then replace with complete medium. Assess gene silencing efficiency at 24–72 hours via qPCR or Western blot.

    3. In Vivo Delivery

    • Formulate complexes as above, scaling doses for animal weight (peptide: 0.2–0.35 mg/kg; nucleic acid: 0.35–0.7 mg/kg).
    • Inject intraperitoneally (i.p.) twice weekly, or administer four consecutive doses for acute studies.
    • Monitor tissue accumulation (epiWAT, subWAT) and gene knockdown (30–70% mRNA reduction) post-treatment. Minimal hepatic or renal toxicity is observed (cell viability >80%).

    These steps streamline targeted gene silencing, outperforming conventional viral vectors in ease, safety, and specificity.

    Experimental Applications and Comparative Advantages

    Gene Silencing for Metabolic Disease Models

    The 2022 JBC study leveraged a FITC-labelled ATS-9R (ATS/sg-FAM83A) to deliver CRISPR-Cas9 components targeting FAM83A in white adipose tissue. Knockdown of FAM83A led to reduced adipocyte size, decreased lipid accumulation, and impaired mitochondrial function, especially under high-fat diet conditions—directly linking this gene to adipogenesis and mitochondrial maintenance. Such mechanistic insights are pivotal for understanding obesity, insulin resistance, and energy metabolism.

    ATS-9R also enables:

    • Attenuation of obesity-associated inflammation by silencing key mediators like TACE and CCL2.
    • Improved insulin sensitivity and amelioration of GDM in preclinical models.
    • Flexible delivery of shRNA, sgRNA/Cas9, or antisense oligos to dissect gene function in adipocyte biology.

    Why Choose ATS-9R Over Alternatives?

    • Non-viral delivery avoids immunogenicity and integration risks associated with viral vectors.
    • White adipose tissue targeting minimizes off-target effects—liver acts as clearance organ, not major site of action.
    • Validated performance: 30–70% knockdown efficiency in vivo, cytotoxicity under 20%, and no adverse hepatic or renal effects.
    • Rapid clearance (12–24 h), supporting repeated dosing or reversible gene modulation.

    These features position ATS-9R as a superior platform for gene silencing in adipocytes and advanced metabolic research.

    Peer-Resource Integration: Complementary Insights

    Troubleshooting and Optimization Tips

    • Suboptimal gene knockdown?
      - Confirm nucleic acid integrity and purity.
      - Verify condensation efficiency: incomplete complexes may show partial migration on agarose gel.
      - Optimize the peptide:nucleic acid ratio (try both 3:1 and 6:1).
    • Cytotoxicity (>20% cell death)?
      - Reduce peptide concentration (start at 10 μg/ml in vitro).
      - Check for DMSO carryover and ensure complete medium replacement post-transfection.
    • Poor targeting/uptake?
      - Use freshly prepared complexes and avoid elevated temperatures.
      - Confirm Prohibitin expression in target adipocytes; primary visceral adipocytes show highest uptake.
    • Inconsistent in vivo results?
      - Standardize injection timing and animal handling.
      - Monitor for hepatic accumulation; adjust dose intervals to avoid peptide saturation in clearance pathways.
    • Batch-to-batch variability?
      - Store ATS-9R at -20°C. Thaw on ice and avoid repeated freeze-thaw cycles.

    For detailed scenario-driven solutions, see the troubleshooting section in Scenario-Driven Best Practices with ATS-9R, which complements these practical tips with community-validated data.

    Future Outlook: Expanding the Toolkit for Adipose Tissue Research

    ATS-9R (Adipocyte-targeting sequence-9-arginine) is catalyzing a shift in metabolic disease research by enabling safe, efficient, and targeted gene manipulation in white adipose tissue. Next-generation applications may include:

    • Multiplexed gene editing in adipocytes to unravel polygenic obesity and diabetes mechanisms.
    • Functional delivery of mRNA or CRISPR activators for gain-of-function studies in adipose biology.
    • Therapeutic translation, leveraging the peptide's rapid clearance and low cytotoxicity for eventual clinical development in obesity or metabolic syndromes.

    As demonstrated in the FAM83A study, ATS-9R empowers researchers to dissect mitochondrial dynamics, lipid metabolism, and gene regulatory networks in adipocytes with unprecedented precision. Coupled with its robust safety and ease of use, ATS-9R from APExBIO stands as an indispensable asset for laboratories aiming to unlock the complexities of white adipose tissue function and its disease associations.

    For ordering and technical information, visit the official product page: ATS-9R (Adipocyte-targeting sequence-9-arginine).